Merimepodib and Remdesivir Against SARS-CoV-2

Published by

Martin Signer activities: Executive, Business Development/Sales, Business Development/Sales, Executive, Business Development/Sales, Business Development/Sales, Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR, IR, IR, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Marketing, Marketing, Marketing, Marketing, Events, Marketing, Marketing, Marketing, Marketing, Marketing, Marketing

May 14, 2020

ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19


Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,   the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics.


Westport, CT, May 14, 2020 (GLOBE NEWSWIRE) --

  • Merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing.  Even at low concentrations of both drugs significant reduction in viral production occurs.
  • Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch

BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, The IMPDH inhibitor merimepodib provided in combination with the adenosine analog remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro” was published by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine, while it is undergoing peer review.

This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, Timothy Wanninger, John T. Manning, Cheng Huang, and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. The link to the manuscript is

The article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. 

“The results of these laboratory investigations have strongly influenced our plans for the initial clinical trials of merimepodib. We have experimental evidence that merimepodib is active as monotherapy and in combination with remdesivir,” commented Jerome Zeldis, M.D., Ph.D.,  Executive Chair and Co-Founder of ViralClear Pharmaceuticals, Inc. “Our first proposed COVID-19 trial is expected to be conducted in hospitalized patients who require supplemental oxygen and receive remdesivir as part of their standard of care.  Patients will be randomized to either placebo or merimepodib. In this manner, the potential synergy between merimepodib and remdesivir may be evaluated in the clinical setting.  An additional trial in the outpatient setting with just merimepodib is proposed to follow the initiation of the first trial.”

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring, and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About ViralClear
BioSig’s subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat advanced COVID-19.

Merimepodib is a broad-spectrum antiviral agent that has demonstrated strong activity against the SARS-CoV-2 virus in cell cultures in laboratory testing. ViralClear plans to initiate a multi-center, phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of merimepodib administered orally three times a day for 10 days in combination with remdesivir administered by intravenous infusion once a day for 5 or up to 10 days in adult patients with advanced COVID-19 upon FDA clearance to proceed. Merimepodib has been studied in twelve clinical trials prior to this planned study, including five trials in patients with hepatitis C (one phase 1b, one phase 2, two-phase 2a, and one phase 2b), one trial in patients with psoriasis (phase 2), and seven trials in healthy volunteers (phase 1). 

Remdesivir is an adenosine analog that displays broad-spectrum antiviral activity against RNA viruses and has been developed by Gilead Pharmaceuticals for the treatment of Ebola. On May 1, 2020, remdesivir received an FDA Emergency Use Authorization to treat COVID-19 in adults and children hospitalized with severe disease.

Articles authored by Martin Signer

Published: Dec 17, 2020

Published: Oct 21, 2020

Published: Sep 2, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 6, 2020

Published: Aug 6, 2020

Published: Aug 4, 2020

Published: Jul 3, 2020

Published: Jun 27, 2020

Published: Jun 11, 2020

Published: Jun 9, 2020

Published: Jun 4, 2020

Published: May 17, 2020

Published: May 12, 2020

Published: May 11, 2020

Published: May 6, 2020

Published: Apr 27, 2020

Published: Apr 26, 2020

Published: Apr 15, 2020

Published: Apr 6, 2020

Published: Mar 24, 2020

Published: Mar 18, 2020

Published: Mar 18, 2020

Published: Mar 18, 2020

Published: Mar 9, 2020

Published: Mar 6, 2020

Published: Mar 4, 2020

Published: Mar 2, 2020

Published: Feb 24, 2020

Published: Feb 18, 2020

Published: Feb 11, 2020

Published: Feb 9, 2020

Published: Jan 17, 2020

Published: Jan 7, 2020

Published: Jan 3, 2020

Published: Dec 25, 2019

Published: Dec 18, 2019

Published: Nov 26, 2019

Published: Nov 6, 2019

Published: Oct 20, 2019

Published: Oct 12, 2019

Published: Oct 11, 2019

Published: Oct 3, 2019

Published: Oct 2, 2019

Published: Oct 1, 2019

Published: Sep 29, 2019

Published: Sep 29, 2019

Published: Sep 19, 2019

Published: Sep 16, 2019

Published: Sep 14, 2019

Published: Sep 5, 2019

Published: Sep 3, 2019

Published: Aug 30, 2019

Published: Aug 29, 2019

Published: Aug 15, 2019

Published: Jul 21, 2019

Published: Jul 8, 2019

Published: Jun 29, 2019

Published: Jun 11, 2019

Published: May 22, 2019

Published: May 5, 2019

Published: Apr 21, 2019

Published: Apr 19, 2019

Published: Mar 28, 2019

Published: Mar 16, 2019

Published: Mar 16, 2019

Published: Mar 6, 2019

Published: Feb 25, 2019

Published: Feb 24, 2019

Published: Feb 7, 2019

Published: Apr 20, 2018

Published: Feb 18, 2018

Published: Feb 7, 2018